CollPlant Biotechnologies (NASDAQ:CLGN) Issues Earnings Results, Beats Estimates By $0.01 EPS

CollPlant Biotechnologies (NASDAQ:CLGN) announced its quarterly earnings data on Friday. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.01, Zacks reports. CollPlant Biotechnologies had a negative return on equity of 161.69% and a negative net margin of 353.70%.The firm had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.46 million.

CollPlant Biotechnologies Stock Down 0.7%

NASDAQ:CLGN opened at $0.40 on Friday. CollPlant Biotechnologies has a 52 week low of $0.27 and a 52 week high of $4.98. The company has a market capitalization of $5.79 million, a P/E ratio of -0.30 and a beta of 1.47. The stock’s fifty day moving average is $0.44 and its two-hundred day moving average is $1.06.

Analysts Set New Price Targets

CLGN has been the topic of a number of analyst reports. Weiss Ratings downgraded CollPlant Biotechnologies from a “sell (e+)” rating to a “sell (e)” rating in a research report on Friday, May 22nd. D. Boral Capital downgraded CollPlant Biotechnologies from a “buy” rating to a “hold” rating in a research report on Friday, February 6th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $11.50.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is a regenerative medicine company that develops and commercializes recombinant human collagen (rhCollagen) and 3D bioprinting technologies for medical and aesthetic applications. The company’s proprietary plant-based rhCollagen is produced using genetically engineered tobacco plants to provide a scalable, animal-free source of human collagen that meets regulatory standards.

CollPlant’s product portfolio includes Vergenix™ wound care matrices and dermal fillers for aesthetic and reconstructive purposes, as well as a range of bioinks designed for 3D bioprinting of soft and hard tissues.